Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Haematological cancer

Idelalisib—targeting PI3Kδ in patients with B-cell malignancies

Idelalisib, the first PI3Kδ inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effects of idelalisib on crosstalk between malignant B cells and the microenvironment.


  1. Friedberg, J. W. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115, 2578–2585 (2010).

    Article  CAS  Google Scholar 

  2. Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32–42 (2013).

    Article  CAS  Google Scholar 

  3. Gopal, A. K. et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med.

  4. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med.

  5. Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031–1034 (2002).

    CAS  Google Scholar 

  6. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 (2009).

    Article  CAS  Google Scholar 

  7. Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 13, 140–156 (2014).

    Article  CAS  Google Scholar 

  8. Burger, J. A. & Gribben, J. G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol. 24, 71–81 (2014).

    Article  CAS  Google Scholar 

  9. Burger, J. A. & Chiorazzi, N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 34, 592–601 (2013).

    Article  CAS  Google Scholar 

  10. Hoellenriegel, J. et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603–3612 (2011).

    Article  CAS  Google Scholar 

Download references


The study was supported by a Cancer Prevention and Research Institute of Texas (CPRIT) grant (to J.A.B.), and a Leukemia & Lymphoma Society Scholar Award in Clinical Research (to J.A.B.).

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jan A. Burger.

Ethics declarations

Competing interests

J.A.B. received research funding from Gilead and Pharmacyclics. K.O. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burger, J., Okkenhaug, K. Idelalisib—targeting PI3Kδ in patients with B-cell malignancies. Nat Rev Clin Oncol 11, 184–186 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer